Clinical Trials on High Risk Haematological Malignancies in Switzerland
Total 22 results
-
Thomas ZilliUniversity Hospital, GenevaRecruitingHaematological MalignancySwitzerland
-
Array BioPharmaCompletedAML | Advanced and Selected Solid Tumors | High Risk and Very High Risk MDSUnited States, Australia, Italy, Spain, France, Switzerland, United Kingdom
-
EMD SeronoTerminatedHaematological MalignanciesItaly, United States, Switzerland, Belgium, Germany
-
Novartis PharmaceuticalsCompletedHematological MalignanciesGermany, Switzerland, France
-
University of ZurichUnknown
-
Luzerner KantonsspitalRecruitingFunctional Iron DeficiencySwitzerland
-
University Hospital Inselspital, BerneCompletedColitis | AML | MucositisSwitzerland
-
Balgrist University HospitalIndustry (Schülke & Mayr AG, Switzerland and Germany)RecruitingElective Surgery | High Risk | Prevention of Surgical Site Infections | Randomized-controlled TrialSwitzerland
-
Rene KahnCompletedUltra High Risk for PsychosisSpain, Austria, Germany, Israel, Italy, Netherlands, Norway, Switzerland, United Kingdom
-
Brigham and Women's HospitalNational Institute of Mental Health (NIMH); Yale University; OrygenRecruitingPsychosis | Remission | Conversion | Clinical High RiskUnited States, United Kingdom, Canada, Italy, Australia, Chile, China, Denmark, Germany, Hong Kong, Korea, Republic of, Singapore, Spain, Switzerland
-
Novartis PharmaceuticalsTerminatedMyelofibrosis With High Molecular Risk MutationsBelgium, Spain, United Kingdom, Hungary, Italy, Japan, Taiwan, Germany, Canada, Singapore, Austria, Australia, France, Israel, Sweden, Switzerland, Hong Kong, Greece, Turkey, Brazil, Russian Federation, Denmark, Portugal, Norway, Poland
-
Amsterdam UMCRecruitingBarrett Esophagus | Submucosal Esophageal Adenocarcinoma | High-risk Mucosal Esophageal AdenocarcinomaNetherlands, Belgium, Australia, United Kingdom, Germany, Switzerland
-
Academisch Medisch Centrum - Universiteit van Amsterdam...UnknownBarrett Esophagus | Adenocarcinoma Esophagus | Submucosal Esophageal Adenocarcinoma | High-risk Mucosal Esophageal AdenocarcinomaFrance, United Kingdom, Belgium, Germany, Switzerland, Australia, Netherlands
-
Bristol-Myers SquibbCompletedHigh Risk Stage III MelanomaItaly, Poland, United Kingdom, United States, Netherlands, Spain, Australia, France, Germany, Canada, Russian Federation, Belgium, Norway, Switzerland, Sweden, Finland, Austria, Denmark, Czechia
-
ECRI bvUniversity of Bern; European Cardiovascular Research Center; Terumo Medical Corporation and other collaboratorsCompletedCoronary Artery Disease | PCI | High Bleeding RiskNetherlands, France, United Kingdom, Australia, Singapore, Japan, Italy, Poland, Spain, Switzerland, Israel, Argentina, Austria, Bahrain, Bangladesh, Belgium, Bulgaria, Czechia, Denmark, Estonia, Germany, Hungary, India, Korea, Republic... and more
-
Cellestia Biotech AGTerminatedBreast Cancer | Adenoid Cystic Carcinoma | Hepatocellular Carcinoma | Colorectal Cancer | Osteosarcoma | Non-hodgkin Lymphoma | Glomus Tumor, Malignant | T-ALLUnited States, Spain, Korea, Republic of, Germany, France, Switzerland
-
Gustave Roussy, Cancer Campus, Grand ParisRecruitingHigh-Risk Neuroblastoma | Patient With Insufficient Response ChemoimmunotherapyFrance, Germany, Israel, Spain, United Kingdom, Belgium, Norway, Sweden, Finland, Australia, Czechia, Italy, Netherlands, Slovenia, Switzerland, Denmark, Greece, Lithuania, Slovakia
-
Ablynx, a Sanofi companyCompletedUnstable Angina | Non ST Segment Elevation Myocardial Infarction (NSTEMI) | Stable Angina (Associated With High Risk PCI)Poland, Belgium, Germany, Israel, Austria, Switzerland, Czechia
-
AmgenTerminatedHigh-risk Diffuse Large B-cell LymphomaUnited States, Italy, Belgium, Switzerland, Australia, France, Greece
-
Mundipharma Research LimitedActive, not recruitingMultiple Myeloma | Hodgkin's Lymphoma | Hematological Malignancies | Cutaneous T Cell LymphomaFrance, United States, Netherlands, Spain, Switzerland, Germany, Italy
-
BayerRecruitingAcute Non-cardioembolic Ischemic Stroke | Prevention of Ischemic Stroke | High-risk Transient Ischemic AttackUnited States, Switzerland, Belgium, Sweden, Canada, Australia, Taiwan, Spain, Korea, Republic of, Latvia, Israel, Malaysia, Greece, Japan, Turkey, Netherlands, Romania, China, United Kingdom, Portugal, Italy, Brazil, France, Slovakia, ... and more
-
Merck Sharp & Dohme LLCRecruitingHigh-risk Non-muscle Invasive Bladder CancerCanada, Belgium, United States, Australia, Austria, France, Germany, Greece, Hungary, Italy, Japan, Korea, Republic of, Malaysia, Netherlands, Peru, Poland, Portugal, Spain, Switzerland, Turkey, United Kingdom, China, Brazil, Colombia, ... and more